Vitamin B6 metabolism in idiopathic sideroblastic anaemia and related disorders.
Patients with idiopathic anaemias associated with abnormal sideroblasts were defined according to morphologic and ferrokinetic criteria and the haematologic and biochemical effects of vitamin B6 therapy were evaluated. While all patients presented similar clinical pictures, peripheral blood changes and bone marrow abnormalities, two distinct groups were identified by sideroblast morphology and ferrokinetics. Patients with more than 5% true ring sideroblasts in the marrow (IRSA) uniformly had marked ineffective erythropoiesis, while those with abnormal sideroblasts but few true ring forms were hypoproliferative. Measurements of red cell pyridoxine kinase (PnK) and intracellular pyridoxal 5-phosphate availability (PLP) as assessed by the activity of the PLP-dependent enzyme asparate aminotransferase (EGOT), revealed slightly decreased PnK levels in IRSA subjects but normal intracellular PLP activities in both groups. Furthermore, when treated with pyridoxine, all patients showed increases in both red cell PnK and EGOT activities which were similar to those seen in normal subjects. Treatment with PLP also effectively increased erythrocyte vitamin B6 activity. Even so, neither pyridoxine nor intramuscular PLP improved erythropoiesis as determined by serial haematocrits, reticulocyte counts and erythron iron turnover measurements.However, since both therapies increased red cell protoporphyrin levels and the excretion of urinary coproporphyrin in a number of subjects, the possibility that impaired haem synthesis in the sideroblastic anaemias is associated with abnormal vitamin B6 metabolism at the level of the mitochondrion must still be considered.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000756:Anemia, Sideroblastic / Q000097:blood* / Q000188:drug therapy; D001219:Aspartate Aminotransferases / Q000097:blood; D004905:Erythrocyte Aging; D004912:Erythrocytes / Q000201:enzymology; D005914:Globins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000097:blood; D007962:Leukocytes / Q000378:metabolism; D008875:Middle Aged; D011166:Porphyrins / Q000097:blood; D011731:Pyridoxal Kinase / Q000097:blood; D011732:Pyridoxal Phosphate / Q000627:therapeutic use; D011736:Pyridoxine / Q000097:blood* / Q000627:therapeutic use
D011166:Porphyrins; D011732:Pyridoxal Phosphate; D005914:Globins; D007501:Iron; D001219:Aspartate Aminotransferases; D011731:Pyridoxal Kinase; D011736:Pyridoxine